









Markets
/
Stocks
/
nasdaq-beam
/

Beam Therapeutics Inc

BEAM

25.390USD

-0.930-3.53%

Close 10/10, 16:00（ET）Quotes delayed by 15 min

2.56BMarket Cap

LossP/E TTM



Beam Therapeutics Inc

25.390

-0.930-3.53%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Beam Therapeutics Inc

Currency: USD Updated: 2025-10-13

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beam Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

75 / 501

Overall Ranking

163 / 4695

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 16 analysts

Buy

Current Rating

44.643

Target Price

+69.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Beam Therapeutics Inc Highlights

StrengthsRisks

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Growing

The company is in a growing phase, with the latest annual income totaling USD 63.52M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 30.32.

Overvalued

The company’s latest PE is -5.66, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 106.40M shares, increasing 1.08% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 10.41M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-13

The company's current financial score is 6.01, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 8.47M, representing a year-over-year decrease of 28.08%, while its net profit experienced a year-over-year decrease of 12.34%.

Score

Industry at a Glance

Previous score

6.01

Change



Financials

6.80

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.25

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Beam Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-13

The company’s current valuation score is 6.32, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -5.66, which is -44.24% below the recent high of -3.15 and -363.98% above the recent low of -26.24.

Score

Industry at a Glance

Previous score

6.32

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-13

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Beam Therapeutics Inc is 42.50, with a high of 80.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 16 analysts

Buy

Current Rating

44.643

Target Price

+69.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Beam Therapeutics Inc

BEAM

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-13

The company’s current price momentum score is 7.24, which is higher than the Biotechnology & Medical Research industry's average of 6.87. Sideways: Currently, the stock price is trading between the resistance level at 29.16 and the support level at 21.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.60

Change

-1.36

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.004

Neutral

RSI(14)

57.891

Neutral

STOCH(KDJ)(9,3,3)

49.945

Sell

ATR(14)

1.528

Low Volatility

CCI(14)

35.440

Neutral

Williams %R

53.760

Neutral

TRIX(12,20)

1.164

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

26.342

Sell

MA10

25.734

Sell

MA20

24.691

Buy

MA50

20.717

Buy

MA100

19.666

Buy

MA200

21.459

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-13

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 105.18%, representing a quarter-over-quarter increase of 5.14%. The largest institutional shareholder is Catherine Wood, holding a total of 10.41M shares, representing 10.29% of shares outstanding, with 21.76% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

12.53M

+64.83%

ARK Investment Management LLC

Star Investors

10.41M

+17.66%

Farallon Capital Management, L.L.C.

10.01M

+0.86%

The Vanguard Group, Inc.

Star Investors

9.69M

+9.47%

BlackRock Institutional Trust Company, N.A.

6.72M

-0.56%

Amova Asset Management Co., Ltd.

4.73M

+10.84%

ARCH Venture Partners

4.54M

State Street Global Advisors (US)

3.64M

+5.76%

Bellevue Asset Management AG

2.89M

+20.59%

Kynam Capital Management LP

2.42M

-3.99%

Risk Assessment

Currency: USD Updated: 2025-10-13

The company’s current risk assessment score is 4.71, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 2.36. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.